10 clinical trials to watch in the second half of 2026
Summary:
Checkout BioPharma Dive list of the top running clinical trials of the remaining 6 months of 2026. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
Ionis, with new FDA nod, hits a ‘commercial inflection point’
Summary:
Ionis Pharmaceuticals’ Tryngolza won a highly anticipated label expansion Wednesday, widening the market for a drug that’s is expected to become a blockbuster.
CRISPR’s next act: the companies editing the epigenome to treat disease
Summary:
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder.
Antares gets $105M from Novartis for new cancer drugs
Summary:
Novartis partnered with Antares Therapeutics in a deal worth up to $1.9 billion, to accelerate the discovery of novel cancer drug targets and further strengthen its expanding oncology pipeline.
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
Summary:
AstraZeneca shared the data behind previously disclosed phase 3 wins, fleshing out the case for an asset tipped to generate blockbuster sales.
